SM
PRTK

Sabby Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Sabby Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,025
Closed -$1.97M – 268
2017
Q1 		$1.97M Buy
+1,025
New +$16.1K 0.11% 95
2013
Q4 		– Sell
-144
Closed -$551K – 252
2013
Q3 		$551K Hold
144
– – 0.04% 153
2013
Q2 		$523K Buy
+144
New +$6.17K 0.03% 141

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Sabby Management's PRTK Position: Q1 2017 in Review

Sabby Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2017, closing a stake of 110,000 shares — an estimated $1.73M sold.

Sabby Management first reported a position in PRTK in Q2 2013 and held it in 10 quarters. The position peaked at $4.26M in Q2 2016. 103 funds tracked by Wall St. Rank hold PRTK as of Q1 2017.

  • Sabby Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Sabby Management sold 110,000 Paratek Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1.73M.
  • Sabby Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and held it in 10 quarters.
  • Sabby Management's Paratek Pharmaceuticals, Inc. position peaked at $4.26M in Q2 2016.
  • 103 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.